
In 2025, the global pharmaceutical trade reflects both growth and tension. While Total EU pharmaceutical exports soared 13.5% in 2024 to a record €313.4 billion, geopolitical strains are emerging, particularly in Switzerland’s case. Understanding what drives export powerhouses like Germany and Switzerland reveals strategic openings in CDMO, biotech, and resilient supply chains
Germany: Volume, Scale, and Consistent Growth
Germany’s pharmaceutical exports reached US$126.1 billion in 2024, up from US$115 billion in 2023, cementing its position as the world’s largest exporter.
Trading Economics
Extra-EU exports totaled €67.9 billion in 2024, with the United States as the primary destination.
Strategy in play: Germany leverages economies of scale, robust R&D pipelines, and an established CDMO infrastructure that remains attractive for value-driven partnerships.
Switzerland: Quality, Pricing, and Tariff Resilience
- Swiss pharmaceutical exports climbed to CHF 149 billion in 2024, a 10% YoY increase, making it a global leader in high-value niches.
- Despite a U.S. tariff spike to 39%, Switzerland’s pharma exports, worth CHF 32.75 billion annually, remain under scrutiny. Pharmaceutical products are currently exempt, but uncertainty continues to cloud the outlook.
- Strengths: Premium positioning, advanced biologics, and a readiness by Roche and Novartis to anchor manufacturing in the U.S. (>$73B commitments) to hedge tariff risks.
EU Context: A Record Export Surplus
In 2024, the EU’s pharmaceutical sector posted a trade surplus of €193.6 billion, marking the highest ever tracked.Germany’s extra-EU strength underscores not just national leadership but regional dominance in market reach.
Strategic Implications for Investors
| Opportunity | Rationale |
| CDMO Partnerships | Germany’s scalable capacity supports tailored outsourcing, ideal for both regional and global pharma players. |
| Biotech Export Niches | Switzerland’s foundation in biologics and premium markets creates high-margin, resilient investment themes. |
| Onshore Resilience | Tariff risks in Switzerland make U.S. production investments (e.g., Roche, Novartis) strategic lifelines |
Germany’s scale and Switzerland’s high-margin specialization continue to shape the global pharma landscape. Export strategies are evolving, and investors must look beyond rankings, into infrastructure, geopolitics, and trade dynamics.
Explore this: Venture Capital and Private Equity: Investment Strategies
Read Our Other Blogs: BLOG